drugset / Trial / NCT03023319
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Timeline
- Start
- 2019-12-10
- Primary completion
- 2022-05-10
- Completion
- 2022-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | 100 mg | Oral |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |